GENFIT Reports First-Half 2026 Financial Results and Provides Corporate Update
Lille (France), Cambridge (Massachusetts, United States); September 28, 2026 — GENFIT Euronext:GNFT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its first half 2026 financial results and provided…